The National Hemophilia Foundation's (NHF) Medical and Scientific Advisory Council (MASAC) issued the following documents, which were adopted by NHF's Board of Directors on June 22, 2012:
MASAC Document #211: MASAC Recommendations Regarding Inhibitor Risk and Recombinant Factor VIII Concentrates
MASAC Document #210: MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders (Revised May 2012)
MASAC Document #209: MASAC Statement on Biosimilars
MASAC Document #208: MASAC Recommendation on Orphan Drugs
To view these documents, click the links above or review the complete list of current MASAC documents. To request a hard copy of any current documents, please contact HANDI, NHF's information resource center: handi@hemophilia.org or 1.800.424.2634.
